Skip to main content
Signal8

InMed Pharmaceuticals Inc. (INM) Form 8-K — Nov 16, 2026

$INMForm 8-KItems 2.01, 2.02, 9.01Filed Nov 16, 2026, 7:03 AM ET0001193125-26-462017Original filing

InMed Pharmaceuticals completed its reverse merger with Mentari Therapeutics on November 6, 2026, with the combined company renamed Mentari Therapeutics, Inc. and led by Mentari's management, focused on migraine-prevention antibodies MT-001 through MT-005. Former Mentari securityholders own approximately 99.0% of the combined company on a fully diluted basis, while former InMed holders retain roughly 1.0%, with InMed valued at just $5.6 million in the deal.

Key figures

Cash Position
45791000
Gross Proceeds
490000000
Total assets
52440000
Rd expense q3
28442000
Exchange ratio
0.20065
Reverse split ratio
1:10
Convertible note rate
12.0%
First price per share
1.8928
Former inmed ownership
1.0%
Rd expense nine months
57709000
Second price per share
2.8923
Former mentari ownership
99.0%
Convertible note principal
50000000
First preclosing financing
290000000
Inmed valuation at closing
5600000
Second preclosing financing
200000000

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.